This low penetrance may reflect the absence of IFN-β neutralization in addition to the neutralization of IFN-α and IFN-ω in IP patients, contrasting with two of the three previously reported patients with YFV adverse reactions (Bastard et al., 2021d). The gene discussed is IFNA2; the disease is incontinentia pigmenti.